Journal of Bioequivalence & Bioavailability

Therapeutic effect of propranolol in Mexican patients with infantile hemangioma

2^nd International Conference & Expo on Biopharmaceutics and Biologic Drugs

September 14-16, 2016 San Antonio, USA

Saul Castaneda

Autonomous University of Baja California, Mexico

Posters & Accepted Abstracts: J Bioequiv Availab

Abstract:

Propranolol, a β-blocker mainly indicated for hypertension, has proven effective in treating Infantile hemangiomas wich are the most common vascular tumors of childhood. The purpose of this study was to evaluate the efficacy and adverse effects of propranolol in Mexican pediatric patients diagnosed with infantile hemangioma, treated with an extemporaneously compounded solution of propranolol. An open prospective observational study at the Childrenâ??s Hospital of the California´s in Tijuana Mexico was performed on ambulatory pediatric patients diagnosed with infantile hemangioma, between the ages of 3-12 months, treated with propranolol in doses ranging from 0.5-2.5 mg/kg/day. Childrenâ??s were monitored monthly by the physician in charge. In a period of 24 months 42 patients were treated. The majority of hemangiomas were superficial (55%), located mainly on the face. Treatment had an average duration of 10.5 months. Ninety-six percent responded to the treatment, showing decreases in size and coloration of the hemangioma. Children who started therapy before five months of age had a significantly better response and shorter duration of treatment. The average therapeutic dose was 1.5 mg/kg/day. Five patients experienced mild adverse effects during the first month of therapy responded to the treatment, showing decrease in size and coloration of the hemangioma. Treatment with propranolol in this group of Mexican pediatric patients, proved to be safe and effective at an average dose of 1.5 mg/kg/day, reducing the size and coloration of hemangioma with a minimum incidence of adverse effects.

Biography :

Email: saulcashe@gmail.com